News
20d
Zacks Investment Research on MSNSanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...
Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to ...
Infant RSV hospitalisations fell 69 per cent in Spain during the 2024 to 2025 season compared with the 2022 to 2023 season, when immunisation therapies were unavailable. Rates decreased almost 27 ...
Medical experts in India are calling for urgent attention to Respiratory Syncytial Virus (RSV), a highly contagious but under-discussed cause of lower respiratory tract infections in infants ...
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus. Skip to content. Main Navigation. Search. Search for: Weather Local Sports ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results